Jazz Pharma Sets July 24 AGM, Focuses on Governance
Ticker: JAZZ · Form: DEF 14A · Filed: Jun 6, 2025 · CIK: 1232524
| Field | Detail |
|---|---|
| Company | Jazz Pharmaceuticals PLC (JAZZ) |
| Form Type | DEF 14A |
| Filed Date | Jun 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Corporate Governance, Annual General Meeting, Shareholder Vote, Pharmaceuticals, SEC Filing, Executive Compensation
Related Tickers: JAZZ
TL;DR
**JAZZ's DEF 14A is a routine governance check, signaling business as usual ahead of the July 24 AGM – no immediate red flags, just standard corporate housekeeping.**
AI Summary
Jazz Pharmaceuticals plc filed its DEF 14A on June 6, 2025, outlining the agenda for its Annual General Meeting on July 24, 2025, in Dublin, Ireland. The filing indicates a focus on standard corporate governance matters, including the election of directors and executive compensation, rather than immediate financial results. While specific revenue and net income figures are not detailed in this proxy statement, the company's consistent filing of definitive proxy statements suggests ongoing operational stability and adherence to regulatory requirements. The document highlights the record date for shareholders to vote as May 29, 2025, emphasizing the importance of shareholder participation in key decisions. Risks are implicitly managed through robust corporate governance structures, and the strategic outlook involves maintaining compliance and ensuring effective leadership through the proposed director elections. The company's business address is Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland, and its phone number is 353-1-634-7800.
Why It Matters
This DEF 14A filing is crucial for investors as it sets the stage for Jazz Pharmaceuticals' 2025 Annual General Meeting, where key corporate governance decisions, including director elections and executive compensation, will be made. These decisions directly impact the company's strategic direction and long-term value creation, influencing investor confidence. For employees, the stability of leadership and compensation structures outlined in such filings can affect morale and retention. Customers and the broader market benefit from a well-governed company, ensuring continued innovation and reliable product supply in the competitive pharmaceutical sector, where Jazz Pharmaceuticals operates with a Standard Industrial Classification of 2834.
Risk Assessment
Risk Level: low — The risk level is low because this is a definitive proxy statement (DEF 14A) for a routine annual general meeting on July 24, 2025. It primarily addresses corporate governance, such as director elections and executive compensation, rather than disclosing new financial risks or significant operational changes. The filing indicates standard regulatory compliance with no unusual or urgent disclosures.
Analyst Insight
Investors should review the specific proposals within the full DEF 14A filing, particularly those related to director elections and executive compensation, to ensure alignment with their investment thesis. Participate in the July 24, 2025, Annual General Meeting by voting by the May 29, 2025, record date to influence corporate governance.
Key Numbers
- 2025-06-06 — Filing Date (Date the DEF 14A was filed with the SEC)
- 2025-07-24 — Annual General Meeting Date (Date shareholders will convene in Dublin)
- 2025-05-29 — Record Date (Date by which shareholders must own stock to vote)
- 99 — Public Document Count (Number of public documents associated with this filing)
Key Players & Entities
- Jazz Pharmaceuticals plc (company) — Registrant and filer of DEF 14A
- SEC (regulator) — Recipient of the DEF 14A filing
- July 24, 2025 (date) — Date of the Annual General Meeting
- May 29, 2025 (date) — Record date for shareholders to vote
- Dublin 4, Ireland (location) — Location of the Annual General Meeting
- 353-1-634-7800 (phone_number) — Business phone number of Jazz Pharmaceuticals plc
- 001-33500 (regulatory_id) — SEC File Number for Jazz Pharmaceuticals plc
- 0001232524 (regulatory_id) — Central Index Key (CIK) for Jazz Pharmaceuticals plc
FAQ
What is the purpose of Jazz Pharmaceuticals' DEF 14A filing?
The DEF 14A filing by Jazz Pharmaceuticals plc is a definitive proxy statement used to inform shareholders about the upcoming Annual General Meeting on July 24, 2025, and to solicit their votes on various corporate matters, including director elections and executive compensation.
When is Jazz Pharmaceuticals' 2025 Annual General Meeting?
Jazz Pharmaceuticals plc will hold its 2025 Annual General Meeting on Thursday, July 24, 2025, at 9:45 a.m. local time, at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.
What is the record date for Jazz Pharmaceuticals shareholders to vote?
The record date for Jazz Pharmaceuticals plc shareholders to be eligible to vote at the 2025 Annual General Meeting is the close of business on May 29, 2025.
Where is Jazz Pharmaceuticals plc's business address?
Jazz Pharmaceuticals plc's business address is Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland, with a business phone of 353-1-634-7800.
What type of company is Jazz Pharmaceuticals plc?
Jazz Pharmaceuticals plc is classified under Standard Industrial Classification 2834, which corresponds to Pharmaceutical Preparations, indicating its primary business is in the pharmaceutical industry.
Does this DEF 14A filing contain Jazz Pharmaceuticals' latest financial results?
No, this DEF 14A filing primarily focuses on corporate governance matters for the upcoming Annual General Meeting and does not typically contain the latest quarterly or annual financial results, which are usually found in 10-K or 10-Q filings.
What is the significance of a DEF 14A filing for Jazz Pharmaceuticals?
A DEF 14A filing is significant for Jazz Pharmaceuticals as it is a mandatory SEC document that provides shareholders with essential information needed to make informed decisions and cast their votes on critical corporate governance issues at the Annual General Meeting.
Who is the filer of this DEF 14A for Jazz Pharmaceuticals?
The filer of this DEF 14A is Jazz Pharmaceuticals Public Limited Company, as specified in its charter, indicating it is the registrant and not a third-party soliciting material.
What is the Central Index Key (CIK) for Jazz Pharmaceuticals plc?
The Central Index Key (CIK) for Jazz Pharmaceuticals plc is 0001232524, which is a unique identifier used by the SEC for all filings.
What are the key items typically voted on at Jazz Pharmaceuticals' Annual General Meeting?
Key items typically voted on at Jazz Pharmaceuticals' Annual General Meeting, as indicated by a DEF 14A, include the election of directors, approval of executive compensation, ratification of the independent auditor, and other shareholder proposals.
Industry Context
Jazz Pharmaceuticals operates within the pharmaceutical preparations industry (SIC 2834). This sector is characterized by significant research and development investment, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection. The industry is also subject to evolving healthcare policies and market access challenges.
Regulatory Implications
As a pharmaceutical company, Jazz Pharmaceuticals is subject to extensive regulatory scrutiny regarding drug development, manufacturing, marketing, and pricing. Compliance with SEC regulations, as evidenced by this DEF 14A filing, is crucial for maintaining investor confidence and operational legitimacy. Changes in healthcare legislation or regulatory enforcement could impact the company's business and financial performance.
What Investors Should Do
- Review the DEF 14A filing for detailed information on director nominees and executive compensation plans.
- Ensure stock ownership is recorded by the May 29, 2025 record date to be eligible to vote.
- Attend or vote by proxy for the Annual General Meeting on July 24, 2025.
Key Dates
- 2025-07-24: Annual General Meeting — Shareholders will vote on key corporate matters, including director elections and executive compensation.
- 2025-05-29: Record Date — Shareholders must own stock by this date to be eligible to vote at the Annual General Meeting.
- 2025-06-06: DEF 14A Filing Date — The proxy statement was filed, providing details for the upcoming Annual General Meeting.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC by publicly traded companies. It contains information that management is sending to shareholders to solicit their votes for the annual meeting. (This document outlines the agenda and proposals for Jazz Pharmaceuticals' Annual General Meeting, including director elections and executive compensation.)
- Annual General Meeting (AGM)
- A formal meeting of a company's shareholders, typically held annually, to discuss company affairs, elect directors, and vote on important resolutions. (The AGM is the primary forum for shareholders to exercise their voting rights on critical company decisions proposed by management.)
- Record Date
- A specific date set by a company to determine which shareholders are eligible to receive dividends, vote on corporate matters, or receive other distributions. (Establishes the cutoff for shareholders to be registered to vote at the upcoming Annual General Meeting.)
Year-Over-Year Comparison
This DEF 14A filing focuses on corporate governance for the upcoming Annual General Meeting on July 24, 2025, rather than providing a detailed comparison of financial performance against the prior year. Specific financial metrics like revenue growth, margin changes, or new risks are not the primary subject of this proxy statement. The consistent filing of such documents indicates ongoing operational stability and adherence to reporting requirements.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 6, 2025 regarding Jazz Pharmaceuticals plc (JAZZ).